Jelle Wesseling MD PhD; 2026 EBCC: ‘Lord’ Trial Finds Active Surveillance for Estrogen-Receptor-Positive, HER2- Negative, Grade 1–2 DCIS Just As Effective as Standard Therapy

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 2AM EDT 5 min · 24 Sep 2026 · NPR News Now

Entertainment Catch-Up: Presley Gerber, Phones in Theatres and Channing Tatum's Troll Account(?) 39 min · 24 Sep 2026 · Catch Up with Louise McSharry

2AM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

How To Naturally Lift & Sculpt Your Face, Define Your Jawline & Age Better Without Injectables 1h 3m · 24 Sep 2026 · The Bossticks

Cómo dejar ir a alguien que todavía amas | Jueves de Lety & Ash | Episodio 697 22 min · 24 Sep 2026 · Se Regalan Dudas

Dead Internet 2026: DARPA, Peter Thiel, Alien AI & Memetic Magick 1h 47m · 24 Sep 2026 · Occult Symbolism and Pop Culture with Isaac Weishaupt

Report any issue

Source

Recorded02 Apr 2026

Publisheraudiomedica.com ↗

Handlerec:19315668

Show notes

At the 2026 EBCC, Jelle Wesseling MD PhD discusses the LORD-trial, which found active surveillance for low-risk, estrogen-receptor-positive, HER2-negative, grade 1–2 DCIS is as effective as standard therapy. The trial's reassuring findings led to early cessation of randomization, supporting de-escal

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in